Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 750-757

  Parker, Chris ^a,b   Milosevic, Michael ^a,b   Toi, Ants ^a,b   Sweet, Joan ^a,b   Panzarella, Tony ^a   Bristow, Rob ^a,b   Catton, Charles ^a,b   Catton, Pamela ^a,b   Crook, Juanita ^a,b   Gospodarowicz, Mary ^a,b   McLean, Michael ^a,b   Warde, Padraig ^a,b   Hill, Richard P ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Prostate neoplasms; Radiotherapy; Tumor hypoxia

Indexed keywords

ANTIGENS; BIOPSY; HEMOGLOBIN; HORMONES; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

POLAROGRAPHIC ELECTRODES; TUMOR OXYGENATION;

ONCOLOGY;

HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRODE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OXYGEN TENSION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; TISSUE OXYGENATION; TUMOR LOCALIZATION;

EID: 10744221495     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01621-3     Document Type: Article

References (32)

1. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 26:1993;45-50.
2. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 20:2002;610-615.
3. Rofstad E.K., Sundfor K., Lyng H., et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer. 83:2000;354-359.
4. Brizel D.M., Dodge R.K., Clough R.W., et al. Oxygenation of head and neck cancer Changes during radiotherapy and impact on treatment outcome . Radiother Oncol. 53:1999;113-117.
5. von Pawel J., von Roemeling R., Gatzemeier U., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer A report of the international CATAPULT I (Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors) study group . J Clin Oncol. 18:2000;1351-1359.
6. Haffty B.G., Hurley R., Peters L.J. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck Results of a randomized clinical trial . Cancer J Sci Am. 5:1999;341-347.
7. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-8 . Radiother Oncol. 46:1998;135-146.
8. Leith J.T., Quaranto L., Padfield G., et al. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo . Int J Radiat Oncol Biol Phys. 25:1993;283-287.
9. Yeh K.A., Biade S., Lanciano R.M., et al. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas Accuracy and reproducibility . Int J Radiat Oncol Biol Phys. 33:1995;111-118.
10. Movsas B., Chapman J.D., Greenberg R.E., et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age. Cancer. 89:2000;2018-2024.
11. Movsas B., Chapman J.D., Horwitz E.M., et al. Hypoxic regions exist in human prostate carcinoma. Urology. 53:1999;11-18.
12. 2 histograph . [3H]misonidazole binding and paired survival assay Radiat Res. 145:1996;491-500.
13. Altman D.G. Practical statistics for medical research. 1991;Chapman and Hall, London.
14. Brizel D.M., Rosner G.L., Prosnitz L.R., et al. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys. 32:1995;1121-1125.
15. Nordsmark M., Bentzen S.M., Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode An analysis of inter- and intratumour heterogeneity . Acta Oncol. 33:1994;383-389.
16. Wong R.K., Fyles A., Milosevic M., et al. Heterogeneity of polarographic oxygen tension measurements in cervix cancer An evaluation of within and between tumor variability, probe position, and track depth . Int J Radiat Oncol Biol Phys. 39:1997;405-412.
17. Littell R.C., Milliken G.A., Stroup W.W., et al. SAS for mixed models. 1996;SAS Institute Inc, Cary, NC.
18. Fleiss J.L. Statistical methods for rates and proportions. 1981;John Wiley & Sons, New York.
19. Rasey J.S., Koh W.J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole A pretherapy study of 37 patients . Int J Radiat Oncol Biol Phys. 36:1996;417-428.
20. 2 predicts for biochemical failure in prostate cancer patients. Int J Radiat Oncol Biol Phys. 51:(Suppl. 1):2001;111.
21. Dachs G.U., Chaplin D.J. Microenvironmental control of gene expression Implications for tumor angiogenesis, progression, and metastasis . Semin Radiat Oncol. 8:1998;208-216.
22. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
23. Ferrer F.F., Miller L.J., Andrawis R.I., et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer In situ and in vitro expression of VEGF by human prostate cancer cells . J Urol. 157:1997;2329-2333.
24. Ferrer F.F., Miller L.J., Andrawis R.I., et al. Angiogenesis and prostate cancer In vivo and in vitro expression of angiogenesis factors by prostate cancer cells . Urology. 51:1998;161-167.
25. Jackson M.W., Bentel J.M., Tilley W.D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic epithelium. J Urol. 157:1997;2323-2328.
26. Cvetkovic D., Movsas B., Dicker A.P., et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology. 57:2001;821-825.
27. Hall M.C., Troncoso P., Pollack A., et al. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology. 44:1994;869-875.
28. Osman I., Drobnjak M., Fazzari M., et al. Inactivation of the p53 pathway in prostate cancer Impact on tumor progression . Clin Cancer Res. 5:1999;2082-2088.
29. Silberman M.A., Partin A.W., Veltri R.W., et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 79:1997;772-779.
30. Levine A.C., Liu X.H., Greenberg P.D., et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 139:1998;4672-4678.
31. Hartley-Asp B., Vukanovic J., Joseph I.B., et al. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol. 158:1997;902-907.
32. Hansen-Algenstaedt N., Stoll B.R., Padera T.P., et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60:2000;4556-4560.